Westpac Banking Corp decreased its holdings in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 6.4% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 41,035 shares of the company’s stock after selling 2,827 shares during the period. Johnson & Johnson accounts for about 0.7% of Westpac Banking Corp’s holdings, making the stock its 25th largest holding. Westpac Banking Corp’s holdings in Johnson & Johnson were worth $10,864,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also recently modified their holdings of the company. CKW Financial Group lifted its stake in shares of Johnson & Johnson by 0.9% in the 3rd quarter. CKW Financial Group now owns 4,269 shares of the company’s stock valued at $1,104,000 after purchasing an additional 37 shares during the period. Silver Coast Investments LLC grew its position in Johnson & Johnson by 3.8% during the 2nd quarter. Silver Coast Investments LLC now owns 1,066 shares of the company’s stock valued at $271,000 after purchasing an additional 39 shares during the last quarter. Townsend Asset Management Corp NC ADV increased its position in shares of Johnson & Johnson by 0.6% during the second quarter. Townsend Asset Management Corp NC ADV now owns 6,418 shares of the company’s stock valued at $1,630,000 after acquiring an additional 39 shares in the last quarter. Triumph Capital Management increased its holdings in shares of Johnson & Johnson by 1.6% in the 2nd quarter. Triumph Capital Management now owns 2,531 shares of the company’s stock worth $643,000 after purchasing an additional 39 shares in the last quarter. Finally, Kwmg LLC boosted its position in shares of Johnson & Johnson by 1.7% during the third quarter. Kwmg LLC now owns 2,383 shares of the company’s stock valued at $631,000 after buying an additional 39 shares during the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.
Johnson & Johnson Stock Performance
NYSE:JNJ opened at $267.02 on Friday. The stock’s fifty day moving average is $267.43 and its 200 day moving average is $250.79. The firm has a market capitalization of $642.80 billion, a PE ratio of 40.46, a PEG ratio of 2.74 and a beta of 0.22. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.74 and a current ratio of 1.02. Johnson & Johnson has a fifty-two week low of $199.90 and a fifty-two week high of $290.25.
Johnson & Johnson Dividend Announcement
The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 8th. Stockholders of record on Tuesday, November 24th will be issued a $1.34 dividend. The ex-dividend date is Tuesday, November 24th. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.0%. Johnson & Johnson’s dividend payout ratio is presently 81.21%.
Wall Street Analysts Forecast Growth
A number of equities analysts have weighed in on the company. Raymond James Financial set a $280.00 target price on Johnson & Johnson in a research report on Monday, August 3rd. JPMorgan Chase & Co. raised their price target on Johnson & Johnson from $270.00 to $285.00 and gave the stock a “neutral” rating in a research note on Tuesday, September 29th. Weiss Ratings lowered shares of Johnson & Johnson from a “buy (b+)” rating to a “buy (b-)” rating in a research report on Friday, October 23rd. Guggenheim restated a “buy” rating and issued a $287.00 price target on shares of Johnson & Johnson in a research report on Wednesday, October 7th. Finally, HSBC increased their price objective on shares of Johnson & Johnson from $290.00 to $320.00 and gave the stock a “buy” rating in a research note on Thursday, September 10th. One analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and eight have given a Hold rating to the company’s stock. Based on data from MarketBeat, Johnson & Johnson presently has an average rating of “Moderate Buy” and a consensus target price of $275.92.
Read Our Latest Research Report on Johnson & Johnson
Insider Transactions at Johnson & Johnson
In other news, EVP Timothy Schmid sold 33,597 shares of the firm’s stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the transaction, the executive vice president owned 25,447 shares in the company, valued at approximately $6,991,308.78. This trade represents a 56.90% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Elizabeth Forminard sold 13,072 shares of the firm’s stock in a transaction dated Thursday, November 12th. The shares were sold at an average price of $284.39, for a total transaction of $3,717,546.08. Following the transaction, the executive vice president directly owned 16,994 shares in the company, valued at $4,832,923.66. This trade represents a 43.48% decrease in their position. The SEC filing for this sale provides additional information. 0.16% of the stock is owned by corporate insiders.
Johnson & Johnson News Summary
These are some of the JNJ news items that stood out recently:
- Positive Sentiment: Memorial Hermann-Texas Medical Center will be the first hospital to install the OTTAVA robotic surgical system as part of an early-access commercial launch. This marks a step toward monetizing the platform following its FDA De Novo authorization. Article
- Negative Sentiment: A Louisiana appeals court upheld a multimillion-dollar talc verdict and an increase in damages, adding to potential legal costs and uncertainty. Separately, Pomerantz LLP announced an investigation into investor claims; the announcement is not a finding of wrongdoing. Appeal ruling article Investor investigation notice
- Negative Sentiment: Healthcare stocks were broadly weaker during Thursday afternoon trading, a sector headwind that may have contributed to pressure on JNJ alongside company-specific news. Sector update
Johnson & Johnson Company Profile
Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech. Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care. Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.
See Also
- Five stocks we like better than Johnson & Johnson
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
